Omnicell (NASDAQ:OMCL) Releases Q2 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) updated its second quarter 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.190-0.320 for the period, compared to the consensus EPS estimate of 0.420. The company issued revenue guidance of $270.0 million-$280.0 million, compared to the consensus revenue estimate of $278.1 million.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Benchmark reaffirmed a "buy" rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $50.67.

Omnicell Stock Down 2.2 %

Shares of NASDAQ:OMCL opened at $30.49 on Tuesday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market cap of $1.43 billion, a PE ratio of 112.93, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The firm has a 50 day simple moving average of $33.28 and a 200 day simple moving average of $40.38.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts expect that Omnicell will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.